Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,847
datasets available to search
ShareScore release 0.9.0
Dataset results
1,847 results for “Psoriasis”
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
ClinicalTrials.gov study NCT01474512. IPD Sharing: Not stated. Countries: 11. Publications: 6.
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
ClinicalTrials.gov study NCT04776629. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov study NCT06011733. IPD Sharing: YES. Countries: 1. Publications: 0.
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
ClinicalTrials.gov study NCT03777436. IPD Sharing: YES. Countries: 7. Publications: 2.
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov study NCT05020249. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
ClinicalTrials.gov study NCT04673786. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
ClinicalTrials.gov study NCT00329303. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
ClinicalTrials.gov study NCT04603027. IPD Sharing: NO. Countries: 4. Publications: 1.
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
ClinicalTrials.gov study NCT01690299. IPD Sharing: YES. Countries: 11. Publications: 3.
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
ClinicalTrials.gov study NCT02326298. IPD Sharing: Not stated. Countries: 5. Publications: 4.
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
ClinicalTrials.gov study NCT00574249. IPD Sharing: Not stated. Countries: 15. Publications: 1.
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
ClinicalTrials.gov study NCT04399837. IPD Sharing: NO. Countries: 23. Publications: 1.
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
ClinicalTrials.gov study NCT02207244. IPD Sharing: Not stated. Countries: 9. Publications: 10.
A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
ClinicalTrials.gov study NCT02518048. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
ClinicalTrials.gov study NCT03818035. IPD Sharing: YES. Countries: 2. Publications: 2.
Using an Internet Study to Improve Adherence for Psoriasis Patients
ClinicalTrials.gov study NCT01802580. IPD Sharing: Not stated. Countries: 1. Publications: 16.
Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis
ClinicalTrials.gov study NCT01111123. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
ClinicalTrials.gov study NCT02054481. IPD Sharing: Not stated. Countries: 7. Publications: 3.
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
ClinicalTrials.gov study NCT03022045. IPD Sharing: YES. Countries: 1. Publications: 1.
High Dose Risankizumab for Psoriasis
ClinicalTrials.gov study NCT05283135. IPD Sharing: NO. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.